The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” could have ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...